For NSCLC patients harboring a sensitizing EGFR-mutation, treatment with EGFR tyrosine kinase inhibitors (TKIs) leads to longer progression-free survival (PFS) and has already become the first-line treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.